• Medientyp: E-Artikel
  • Titel: Description of a European memory clinic cohort undergoing amyloid‐PET: The AMYPAD Diagnostic and Patient Management Study
  • Beteiligte: Altomare, Daniele [VerfasserIn]; Collij, Lyduine [VerfasserIn]; Poitrine, Léa [VerfasserIn]; Delrieu, Julien [VerfasserIn]; Payoux, Pierre [VerfasserIn]; Saint-Aubert, Laure [VerfasserIn]; Molinuevo, José Luis [VerfasserIn]; Grau-Rivera, Oriol [VerfasserIn]; Gispert, Juan-Domingo [VerfasserIn]; Minguillón, Carolina [VerfasserIn]; Fauria, Karine [VerfasserIn]; Sanchez, Marta Felez [VerfasserIn]; Caprioglio, Camilla [VerfasserIn]; Rădoi, Andreea [VerfasserIn]; Drzezga, Alexander [VerfasserIn]; Jessen, Frank [VerfasserIn]; Escher, Claus [VerfasserIn]; Zeyen, Philip [VerfasserIn]; Nordberg, Agneta [VerfasserIn]; Savitcheva, Irina [VerfasserIn]; Jelic, Vesna [VerfasserIn]; Walker, Zuzana [VerfasserIn]; Lee, Ho-Yun [VerfasserIn]; Scheltens, Philip [VerfasserIn]; [...]
  • Erschienen: Wiley, 2023
  • Erschienen in: Alzheimer's and dementia 19(3), 844-856 (2023). doi:10.1002/alz.12696
  • Sprache: Englisch
  • DOI: https://doi.org/10.1002/alz.12696
  • ISSN: 1552-5260; 1552-5279
  • Entstehung:
  • Anmerkungen: Diese Datenquelle enthält auch Bestandsnachweise, die nicht zu einem Volltext führen.
  • Beschreibung: Introduction: AMYPAD Diagnostic and Patient Management Study (DPMS) aims to investigate the clinical utility and cost-effectiveness of amyloid-PET in Europe. Here we present participants' baseline features and discuss the representativeness of the cohort.Methods: Participants with subjective cognitive decline plus (SCD+), mild cognitive impairment (MCI), or dementia were recruited in eight European memory clinics from April 16, 2018, to October 30, 2020, and randomized into three arms: ARM1, early amyloid-PET; ARM2, late amyloid-PET; and ARM3, free-choice.Results: A total of 840 participants (244 SCD+, 341 MCI, and 255 dementia) were enrolled. Sociodemographic/clinical features did not differ significantly among recruiting memory clinics or with previously reported cohorts. The randomization assigned 35% of participants to ARM1, 32% to ARM2, and 33% to ARM3; cognitive stages were distributed equally across the arms.Discussion: The features of AMYPAD-DPMS participants are as expected for a memory clinic population. This ensures the generalizability of future study results.Keywords: Alzheimer's; PET; amyloid; dementia; memory clinic population; mild cognitive impairment; subjective cognitive decline.
  • Zugangsstatus: Freier Zugang